ASEAN Point of Care Diagnostics Companies

The ASEAN point of care diagnostics market is anticipated to grow from USD 1.08 billion in 2025 to reach USD 1.36 billion by 2030, at a CAGR of 4.7% during the forecast period. The increasing prevalence of chronic diseases and infectious diseases is fueling the demand for POC testing in the region. The demand for immediate and rapid diagnostic products is becoming increasingly significant in facilitating early detection and treatment. Additionally, supportive government policies in funding initiatives and healthcare regulations for enhanced diagnostic accessibility are also expected to fuel the uptake of POC tests.

The key players in this market are Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan), Danaher Corporation (US), BD (US), QuidelOrtho Corporation (US), Cardinal Health (US), AccuBioTech Co., Ltd. (China), EKF Diagnostics Holdings plc (UK), bioMérieux (France), and Thermo Fisher Scientific Inc. (US). These market players have adopted product launches, partnerships, collaborations, expansions, and acquisitions to strengthen their positions in the ASEAN point of care diagnostics market. The uptake of organic & inorganic strategies has helped these market players expand their business operations across several regions.

To know about the assumptions considered for the study download the pdf brochure

Abbott is a dominant player in the ASEAN point of care diagnostics market, with a comprehensive portfolio of diagnostic products, such as blood screening tests, glucometers, and clinical chemistry systems. Its global reach supports its ability to build on its presence in developed and emerging economies. Abbott maintains its competitive advantage by focusing on ongoing innovation and R&D investments. Introducing new products and approving regulatory clearances have further augmented its leadership in the market. For instance, in April 2024, the company's i-STAT TBI cartridge received the US FDA clearance to be used with whole blood, further strengthening its position in the POC diagnostics market.

F. Hoffmann-La Roche Ltd. is a leading company in the ASEAN point of care diagnostics market, well known for its leadership in the global diagnostics market. The company's wide product portfolio and extensive international presence have established a strong competitive position. Roche has established distribution channels that balance both organic & inorganic strategies, further enhancing its position in the POC diagnostics market. For instance, in January 2025, Roche gained the US FDA 510(k) clearance and CLIA waiver for its cobas liat sexually transmitted infection (STI) multiplex assay panels, which are intended for point of care STI diagnosis. Such developments contribute to its market position in the point of care diagnostics market.

Siemens Healthineers AG is a leading player in the ASEAN point of care diagnostics market, offering a broad range of POC solutions such as clinical chemistry platforms and immunodiagnostic systems capable of providing rapid & accurate test results at the patient's bedside. The firm continues proactively building its POC business by entering strategic alliances and partnerships to enhance diagnostic performance and operational effectiveness across various care environments. With a global presence across over 70 countries, the company is positioned to enable healthcare systems to improve patient outcomes via accessible and prompt diagnostic tests at the point of care.

Market Ranking

The ASEAN point of care diagnostics market is consolidated, and the top 5 players are Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Sysmex Corporation, and Danaher Corporation. Abbott dominates the market with its robust portfolio of point of care rapid diagnostic tests, most notably infectious disease testing, which are broadly accepted in clinical & decentralized healthcare environments. Roche has a strong presence fueled by its cobas and Accu-Chek POC platforms, which also experience strong demand in both acute & chronic disease management opportunities. Siemens Healthineers has established a competitive position based on its full range of blood gas, urinalysis, and cardiac marker test systems, which find widespread use in critical care settings.

Sysmex has a significant market share, especially in hematology and urinalysis POC systems, due to its strong brand reputation for high-precision and reliable instruments.

Danaher continues to find increasing market acceptance through its subsidiaries like Cepheid by providing molecular POC solutions that respond to the increasing demand for rapid, accurate, and decentralized infectious disease diagnosis.

Regional and emerging players share the rest of the market, leading to a fragmented competitive environment. Continuous innovation, rigorous regulatory compliance, and the increasing demand for rapid, easy-to-use diagnostic devices are the primary factors fueling the ASEAN point of care diagnostics market growth.

Related Reports:

ASEAN Point of Care Diagnostics Market by Product (Infectious Disease (TB, Hepatitis, STDs, HAIs), Glucose, Cardiometabolic, Pregnancy, Coagulation), Technology (Lateral Flow Assays, Biochemistry, MDx), End User (Home Care, Hospitals) - Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com